Sign in

    Colleen Babington

    Research Analyst at Wolfe Research, LLC

    Colleen Babington is an Equity Research Associate at Wolfe Research, LLC, specializing in healthcare sector coverage with a focus on companies such as GRAIL and Natera. Her role involves detailed financial and operational analysis of leading life science and biotechnology firms, participating in company earnings calls and contributing to institutional research reports. Babington began her career in equity research and joined Wolfe Research as an associate, where she has become known for her analytical rigor and sector expertise. She holds relevant professional credentials for equity research, although specific FINRA registrations or securities licenses are not publicly listed.

    Colleen Babington's questions to GRAIL (GRAL) leadership

    Colleen Babington's questions to GRAIL (GRAL) leadership • Q2 2025

    Question

    Colleen Babington of Wolfe Research asked about GRAIL's international expansion strategy, specifically how the NHS Galleri data will be used to engage with single-payer systems, and whether international growth would require new lab facilities.

    Answer

    CEO Bob Ragusa highlighted significant inbound global interest and described the upcoming NHS Galleri study results as a 'great calling card' for discussions with other countries. President of International Business Harpal Kumar added that the study's rigor and the NHS's reputation are expected to help convert global interest into meaningful growth opportunities.

    Ask Fintool Equity Research AI

    Colleen Babington's questions to Cars.com (CARS) leadership

    Colleen Babington's questions to Cars.com (CARS) leadership • Q2 2025

    Question

    Colleen Babington of Wolfe Research asked about the future trajectory of operating expenses, specifically whether R&D spend would stabilize, and queried the balance between sales and marketing investment versus R&D.

    Answer

    SVP & CFO Luke Power confirmed that R&D spend is expected to remain relatively flat, as the primary investment in the universal assay platform is complete. An executive (likely EVP & Vice Chairman Brian Brille) highlighted significant operating leverage, noting that case volumes have doubled in recent years while the sales team size has been stable, indicating no immediate need to shift spending from R&D to sales.

    Ask Fintool Equity Research AI

    Colleen Babington's questions to Cars.com (CARS) leadership • Q2 2025

    Question

    Colleen Babington, on for Doug Schenkel, asked about operating expenses, specifically if R&D spend would stabilize due to a focus on computational work and whether the company might reallocate spending from R&D to sales and marketing to build brand recognition.

    Answer

    Luke Power, SVP, CFO & Chief Accounting Officer, confirmed that R&D spend is expected to remain flat as the major investments in the universal assay are complete. Dr. David Spetzler, President, added that while large studies are ongoing, the bulk of the investment has been made. An executive highlighted the significant operating leverage in the sales force, noting that volumes have doubled in recent years with a flat sales team headcount, negating the need to shift spending.

    Ask Fintool Equity Research AI

    Colleen Babington's questions to Cars.com (CARS) leadership • Q2 2025

    Question

    Colleen Babington of Wolfe Research, LLC, on behalf of Doug Schenkel, asked about the focus of R&D spending, potential costs from large clinical studies, and the company's ability to leverage its sales and marketing infrastructure.

    Answer

    SVP & CFO Luke Power stated that R&D spending is expected to remain flat, as the primary investment in the universal Caris Assure assay platform is complete. President David Spetzler added that major investments for upcoming studies have already been made. EVP & Vice Chairman Brian Brille highlighted significant operating leverage, noting that case volumes have doubled in recent years while the sales force size has remained stable.

    Ask Fintool Equity Research AI

    Colleen Babington's questions to Natera (NTRA) leadership

    Colleen Babington's questions to Natera (NTRA) leadership • Q1 2025

    Question

    Colleen Babington, on for Doug Schenkel, asked for a breakdown of the strong prenatal volume growth, an update on ACOG guidelines for microdeletions, and inquired about Signatera's indication mix and the impact of biomarker laws on commercial reimbursement.

    Answer

    CEO Steve Chapman explained that prenatal growth was proportional across the portfolio, led by NIPT and carrier screening. He noted that while ACOG guideline timing is unknown, they represent significant future upside, especially for the ~1 million annual 22q tests that are currently unreimbursed. An executive added that breast cancer is a major growth driver for Signatera and that the primary commercial reimbursement challenge remains broad payer coverage, which biomarker laws are beginning to positively influence.

    Ask Fintool Equity Research AI

    Colleen Babington's questions to VERACYTE (VCYT) leadership

    Colleen Babington's questions to VERACYTE (VCYT) leadership • Q1 2025

    Question

    Colleen Babington, on for Doug Schenkel, asked about the Decipher ASP and volume outlook following the metastatic launch. She also questioned how the MRD test is differentiated, how its higher COGS will be managed, and if reimbursement will be ready at launch.

    Answer

    CFO Rebecca Chambers projected a stable Decipher ASP, as a higher Medicare mix in metastatic is offset by initial lack of commercial coverage. On MRD, CEO Marc Stapley highlighted the key differentiator is its 93-day lead time in detecting recurrence over imaging. Chambers added that while COGS are higher, a strong Medicare ASP and a multiyear cost-down plan will ensure the platform is accretive to adjusted EBITDA over time. She confirmed the plan is to launch with reimbursement in place.

    Ask Fintool Equity Research AI